Management of Patients with Hereditary Angioedema During the COVID-19 Pandemic

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: The aim of this study was to determine the clinical course and treatment outcomes of patients with hereditary angioedema (HAE) after infection with coronavirus disease 2019 (COVID-19). Materials and Methods: Thirty-nine patients with HAE were included in this study. These patients were regularly followed up over phone calls since the first COVID-19 case was seen in our country. Patients were asked to visit the hospital if there was a history of contact with a confirmed COVID-19 patient or if the patient developed clinical symptoms of COVID-19. Results: There were 21 (54%) patients with type I HAE, and 18 (46%) with type II HAE. All patients received treatment for angioedema attacks (C1-inhibitor [C1-INH], icatibant), and seven (20%) received long-term prophylaxis (danazol). Treatment for attacks was continued for all patients during the pandemic. Patients taking danazol were switched to long-term prophylaxis using the C1-INH concentrate. Eleven (28%) patients with HAE developed COVID-19 during this study. Only one patient had severe COVID-19. Six patients (54.5%) were diagnosed with type II HAE, and five (45.5%) were diagnosed with type I HAE. The most common COVID-19 symptoms were fever (7/11; 64%) and myalgia (6/11; 55%). Mild angioedema attacks were experienced by 36% (4/11) of the HAE patients diagnosed with COVID-19. Icatibant was used in all patients. Conclusion: Agents used for HAE block the kallikrein-kinin system and may be useful in the treatment of COVID-19. Considering their beneficial effects on COVID-19, it is recommended that HAE patients should continue the use of agents blocking the kallikrein-kinin system.

References Powered by Scopus

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

14657Citations
N/AReaders
Get full text

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

2787Citations
N/AReaders
Get full text

Coagulation abnormalities and thrombosis in patients with COVID-19

1139Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yildiz, E., Arslan, Ş., Çölkesen, F., Aykan, F. S., Evcen, R., & Kilinç, M. (2021). Management of Patients with Hereditary Angioedema During the COVID-19 Pandemic. Asthma Allergy Immunology, 19(3), 166–173. https://doi.org/10.21911/AAI.661

Readers' Discipline

Tooltip

Medicine and Dentistry 2

100%

Save time finding and organizing research with Mendeley

Sign up for free